Revenue: As of FY2025 Q2, the actual value is USD 11.21 M.

EPS: As of FY2025 Q2, the actual value is USD -0.27.

Segment Revenue

• Revenue: $11,213 for the three months ended June 30, 2025, compared to $7,364 for the same period in 2024, representing a 52.3% increase.

Operational Metrics

• Gross Profit: $9,411 for the three months ended June 30, 2025, compared to $6,452 for the same period in 2024, representing a 45.9% increase.
• Loss from Operations: - $7,332 for the three months ended June 30, 2025, compared to - $8,174 for the same period in 2024.
• Net Loss: - $8,288 for the three months ended June 30, 2025, compared to - $4,332 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $11,819 for the six months ended June 30, 2025, compared to - $24,289 for the same period in 2024.
• Net Cash Provided by Financing Activities: $30,405 for the six months ended June 30, 2025, compared to $29,119 for the same period in 2024.

Unique Metrics

• Change in Fair Value of SEPA, Warrant, and Revenue Base Redemption Liabilities: - $330 for the three months ended June 30, 2025, compared to - $9,016 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue the commercialization of TriNav and expand its market presence, leveraging new product launches such as TriNav LV and TriNav FLX to enhance therapeutic delivery capabilities.
• Non-Core Business: The company is exploring partnerships for further development of nelitolimod, aiming to address barriers in the tumor microenvironment that inhibit the success of immunotherapy.
• Priority: The company is focused on maintaining its current TriNav pricing and gross margins to support growth and R&D activities.